Immunology
Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune diseases. The company that is developing the platform, Precigen ActoBio, is advancing a lead candidate through clinical trials with the long-term goal of finding a sweet spot between biologics and gene therapies.  Discuss
Highlights from the AACR virtual meeting II
The American Association for Cancer Research (AACR) annual meeting in virtual format featured a broad array of sessions, discussing many aspects of cancer research from drug development to treatment and patient advocacy.  Discuss
Scientists urge that surveillance of a new SARS-CoV-2 variant is necessary
A SARS-CoV-2 variant carrying an amino acid change, D614G, in the spike protein has become the predominant form of the virus in the current global pandemic. A recent publication in Cell advocated for viral surveillance to aid in the development of immunological interventions.  Discuss
Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized vaccines for individual cancer patients. Researchers from BioNTech and the Wistar Institute shared exciting developments in cancer vaccines in a methods workshop during the American Association for Cancer Research 2020 virtual annual meeting II.  Discuss
From DNA to precision medicine, researchers discuss breakthroughs in cancer research
From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer, researchers from around the globe shared their progress with the cancer research community on June 22 at the opening plenary session of the American Association for Cancer Research 2020 virtual annual meeting II.  Discuss
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.  Discuss
Are interferons a viable therapeutic intervention for COVID-19?
Significantly improved viral clearance and reductions in inflammatory cytokines are observed in COVID-19 patients treated with interferons, according to an exploratory study published in Frontiers in Immunology on May 15.  Discuss
Researchers explore role of cytokine storm in severe COVID-19
An overreaction of the immune system to SARS-CoV-2 -- a phenomenon known as cytokine storm -- has emerged as a major contributor to patient mortality during the COVID-19 outbreak. In a recent series of papers, authors examined cytokine storm and offered perspectives on preventing it from occurring.  Discuss
Pangolin genome offers insight into SARS-CoV-2's jump to humans
Research into the source of SARS-CoV-2 in China has focused on pangolins, anteater-like mammals that may have harbored the virus before it jumped to humans. New findings published May 8 in Frontiers in Immunology indicate pangolins may lack two virus-sensing genes, making them more susceptible to being carriers of coronaviruses.  Discuss
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents the SARS-CoV-2 virus from infecting cultured cells. Authored by a team of researchers from Utrecht University, Erasmus Medical Center, and Harbour BioMed, the report was published in Nature Communications on May 4.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter